Roivant's Eye-Disease Drug Aces Two Late-Stage Trials — But Can a $27 Billion Biotech Keep Delivering Without Revenue?

Shares surged 7.6% to $37.56 as Roivant Sciences delivered dual Phase 3 wins this morning for its lead anti-inflammatory drug in a rare eye disease, reinforcing its claim to a growing immunology franchise — while investors weigh whether the stock's tripling since late 2024 has already priced in good news.

• Two Identical Trials Hit Every Endpoint, Setting Up a New FDA Filing. Brepocitinib 45 mg once-daily achieved statistically significant benefit on the primary and all key secondary endpoints in both the CLARITY-1 and CLARITY-2 Phase 3 trials in non-infectious uveitis.

Median time to treatment failure exceeded 48 weeks on the drug, versus roughly 12 weeks on placebo (p<0.0001).

Priovant intends to submit a supplemental New Drug Application for this indication in the first half of 2027. NIU — a rare inflammatory eye condition that can cause blindness — has only one approved non-steroid therapy, making the commercial opportunity wide open.

• The Drug Is Already Approved Elsewhere, and the Pipeline Keeps Expanding. Brepocitinib is already FDA-approved for dermatomyositis (marketed as LISRAYA) and is also in late-stage development for cutaneous sarcoidosis and lichen planopilaris. Each positive readout builds the case that this single molecule could serve multiple rare autoimmune conditions — a playbook that generates recurring prescriptions across diseases without needing separate drug discovery programs.

• A $4.3 Billion Cash Pile Funds Growth — But Losses Continue. As of March 31, 2026, Roivant held $4.3 billion in cash and marketable securities.

The company already repurchased $1.3 billion in stock, reducing share count by nearly 15%. That buyback boosted per-share value, yet quarterly R&D spending rose to $198.9 million , and Roivant still generates negligible revenue — just $8 million annually against a $28.6 billion market cap.

• The Valuation Bets on a Future That Hasn't Arrived. Roivant's market cap has increased 154% in one year , powered by clinical wins and capital return. But at roughly $27 billion today, the stock prices in blockbuster sales across multiple indications before the first major launch has matured. Any trial stumble or slower-than-expected NIU uptake could quickly test investor patience with a company still burning cash at a nine-figure quarterly pace.